Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Amydis, Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being reviewed by 1 distinct examiner within 1 distinct art unit. This reflects a highly concentrated prosecution strategy with no current diversification across different patent office personnel or administrative divisions.
YOUNG, MICAH PAUL is the busiest examiner for this portfolio, currently responsible for 1 pending office action. Since the total count of pending actions is 1, this examiner handles all of the company's active prosecution. This concentration of the workload under one official means that the prosecution outcome depends on a single set of examiner perspectives. There are no other active cases to provide a broader range of interactions with the patent office at this time.
The involvement of 1 distinct art unit indicates a focused technical review for the current active portfolio. For practitioners, this means that the 1 pending office action is subject to the specific standards of a single art unit. The busiest examiner pending count of 1 matches the total workload, confirming the singular focus of the current filings within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760854 | METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN | YOUNG, MICAH PAUL | 53d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17760854 | METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 53d | Pending | Mar 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmydis, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Micah Paul Young has the most, with 1 of Amydis, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
